Lung Cancer News

Pyrotinib Shows Activity in HER2-Positive Non-Small Cell Lung Cancer

Pyrotinib Shows Activity in HER2-Positive Non-Small Cell Lung Cancer

Pyrotinib showed activity in HER2-positive non-small cell lung cancer, both in preclinical experiments and in patients enrolled in a phase 2 trial.

Analysis of Durvalumab Consolidation Therapy Costs in Stage III NSCLC

Analysis of Durvalumab Consolidation Therapy Costs in Stage III NSCLC

Use of durvalumab consolidation therapy in all eligible patients with NSCLC was deemed cost-effective, despite its incremental budgetary consequence of $768 million in year 1.

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

Tecentriq Combination Regimen Approved for Metastatic Non-Squamous NSCLC

The approval was based on data from the IMpower 150 trial, an open-label study involving 1202 patients with stage IV metastatic NSq NSCLC who had not received prior chemotherapy for metastatic disease, but could have received prior EGFR or ALK kinase inhibitor if appropriate, regardless of PD-L1 or T-effector gene status and ECOG performance status 0 or 1.

Adjuvant Erlotinib May Benefit Patients With Early-Stage Non-Small Cell Lung Cancer

Adjuvant Erlotinib May Benefit Patients With Early-Stage Non-Small Cell Lung Cancer

Researchers found that recurrences were rare for patients receiving adjuvant erlotinib.

Percutaneous Microwave Thermal Ablation May be Effective in Primary Lung Malignancy

Percutaneous Microwave Thermal Ablation May be Effective in Primary Lung Malignancy

Researchers reported that ablation of pulmonary malignant tumors may be a safe treatment option in select patients.

MET-Inhibitor Combination Shows Activity in EGFR-Mutated, MET-Dysregulated NSCLC

MET-Inhibitor Combination Shows Activity in EGFR-Mutated, MET-Dysregulated NSCLC

Combination therapy showed activity in epidermal growth factor receptor-mutated, mesenchymal-epithelial transition factor-dysregulated non-small-cell lung cancer.

Further Development of Hsp90 Inhibitor in NSCLC Remains Uncertain

Further Development of Hsp90 Inhibitor in NSCLC Remains Uncertain

This trial in NSCLC was terminated early when the investigational drug become unavailable following the dissolution of a partnership between the drug's codevelopers.

ctDNA Helped Predict Response, Survival After Durvalumab in Lung, Bladder Cancer

ctDNA Helped Predict Response, Survival After Durvalumab in Lung, Bladder Cancer

Analyzing ctDNA following drug treatment could help identify nonresponders to immunotherapy.

Efforts Made in the 1960s to Curb Smoking Will Have Effects Well Into Future

Efforts Made in the 1960s to Curb Smoking Will Have Effects Well Into Future

Scientific models project a continued decrease in lung cancer mortality.

Management of Hyperprogressive Disease in Nivolumab-Treated Lung Cancer

Management of Hyperprogressive Disease in Nivolumab-Treated Lung Cancer

Management strategies were identified for lung cancer patients who experienced hyperprogressive disease during treatment with nivolumab.

First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC

First-Line Alectinib Effective in Asian Patients With ALK-Positive Advanced NSCLC

Alectinib substantially improved outcomes in Asian patients with treatment-naive, ALK-positive NSCLC.

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

Atezolizumab Combo Improved PFS, OS in Stage IV Non-Small Cell Lung Cancer

Significant improvements were seen with the addition of atezolizumab to CnP in stage IV non-squamous non-small cell lung cancer, regardless of patient PD-L1 status.

Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib

Resistance Mechanisms Identified for NSCLC Progression With First-Line Osimertinib

The 2 most common resistance mechanisms were MET amplification, EGFR C797S mutation.

Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib

Brigatinib Found More Effective for ALK-positive NSCLC Brain Mets Compared With Crizotinib

Brigatinib significantly delayed time to intracranial progression and prolonged PFS compared with crizotinib in patients with ALK+ NSCLC with intracranial metastases.

Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers

Plasma NGS Should Be Routine in Metastatic NSCLC, Say Researchers

Approximately one-third of patients with NSCLC with a therapeutically targetable mutation detected in plasma were able to avoid invasive biopsy.

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Immune-Related Adverse Events Due to Checkpoint Inhibition Are More Common in Melanoma Than in NSCLC

Researchers investigated whether the rates of immune-related adverse events linked to treatment with nivolumab or pembrolizumab were similar across 2 different cancer types.

Only One-Third of Trials Supporting FDA Approval of Cancer Drugs Met the ESMO-MCBS Criteria for Substantial Clinical Benefit

Only One-Third of Trials Supporting FDA Approval of Cancer Drugs Met the ESMO-MCBS Criteria for Substantial Clinical Benefit

The only single-arm cancer trials to show a substantial benefit were those for osimertinib for T790-mutated NSCLC and crizotinib for ALK-rearranged NSCLC.

Perspectives on Combination Immunotherapy in NSCLC

Perspectives on Combination Immunotherapy in NSCLC

Many immunotherapy-based combinations are being studied in NSCLC, with TMB emerging as a potential predictive biomarker.

Tislelizumab Shows Antitumor Activity in Lung Cancer

Tislelizumab Shows Antitumor Activity in Lung Cancer

Tislelizumab, an anti-PD-1 antibody, demonstrated antitumor activity in phase 1 and phase 2 trials of Chinese patients with advanced lung cancers.

CT Screening Reduces Lung Cancer Deaths in High-Risk Asymptomatic Patients

CT Screening Reduces Lung Cancer Deaths in High-Risk Asymptomatic Patients

CT lung cancer screening substantially reduces lung cancer deaths among asymptomatic patients at high risk for developing lung cancer.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs